The ground is finally starting to break.
After researching and studying scientific reality, the U.S. Food and Drug Administration (FDA) green-lighted a CBD-based medical treatment for two types of epilepsy, according to npr.org.
Epidiolex will be prescribed to treat both Dravet syndrome and Lennox-Gastaut syndrome, ailments first detected in childhood and that can continue to cause health issues into adulthood.
The new drug is created via purified cannabidiol (CBD), which is a compound of the cannabis plant. CBD does not induce “highs” like tetrahydrocannabinol (THC), which is the plant’s psychoactive ingredient, but has proven useful in treating a wide range of ailments. FDA advisers gave Epidiolex their collective nod of approval in April.
Epidiolex will be the first approved drug for the treatment of Dravet syndrome, and the first FDA-approved drug derived from a cannabis plant. Previously, the FDA said it legalized certain synthetic forms of marijuana, including THC, npr.org reported.
During a conference call with reporters, FDA Commissioner Dr. Scott Gottlieb was quoted as saying: “This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.”
To treat the rare and severe ailments, Gottlieb made a point to announce the CBD ruling is not a vote of confidence for the legalization of recreational marijuana. Anyone seeking cannabis-based medicine will need to prove it’s beneficial and safe, nbcnews.com reported.
That being said, it’s hard not to see this at least opening the door to a wider range of CBD-based medical treatment options — which is certainly progress.